产品
编 号：F206507
分子式：C26H27BrF3N5O2
分子量：578.42
分子式：C26H27BrF3N5O2
分子量：578.42
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
结构图
CAS No: 1715025-32-3
产品详情
生物活性：
Rineterkib (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF.
体内研究：
Rineterkib (化合物 B) (50、75 mg/kg，po，qd/q2d，27 天) 处理可显著减少小鼠 Calu-6 人 NSCLC 皮下肿瘤异种移植模型的肿瘤体积。Animal Model:Calu-6 NSCLC xenograft tumor models in mice.
Dosage:50, 75 mg/kg.
Administration:Orally either daily (qd) or every other day (q2d) for 27 days.
Result:Significantly reduced the tumor volume.
Rineterkib (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF.
体内研究：
Rineterkib (化合物 B) (50、75 mg/kg，po，qd/q2d，27 天) 处理可显著减少小鼠 Calu-6 人 NSCLC 皮下肿瘤异种移植模型的肿瘤体积。Animal Model:Calu-6 NSCLC xenograft tumor models in mice.
Dosage:50, 75 mg/kg.
Administration:Orally either daily (qd) or every other day (q2d) for 27 days.
Result:Significantly reduced the tumor volume.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备